Used in research and development of targeted cancer therapies, particularly in cancers where NOTCH3 signaling is dysregulated, such as ovarian, breast, and T-cell acute lymphoblastic leukemia (T-ALL). This antibody serves as a critical tool for validating NOTCH3 as a therapeutic target and for evaluating the efficacy of anti-NOTCH3 drug candidates. It enables precise detection and modulation of NOTCH3 receptor activity in cellular and animal models. Due to its high specificity, it supports studies in signal transduction pathways and helps in the design of antibody-drug conjugates or blocking antibodies for clinical use. Also employed in immunohistochemistry and flow cytometry to assess NOTCH3 expression in tumor tissues.